The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021
Open accessAbstract
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson; New Brunswick, New Jersey), and on February 28, 2021, the Advisory Committee on Immunization Practices (ACIP) issued interim recommendations for its use in persons aged ≥18 years (1,2). On April 13, 2021, CDC and FDA recommended a pause in the use of the Janssen COVID-19 vaccine after reports of six U.S. cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia, a rare thromboembolic syndrome, among Janssen COVID-19 vaccine recipients (3). Two emergency ACIP meetings were rapidly convened to review reported cases of thrombosis with thrombocytopenia syndrome (TTS) and to consider updated recommendations for use of the Janssen COVID-19 vaccine in the United States. On April 23, 2021, after a discussion of the benefits and risks of resuming vaccination, ACIP reaffirmed its interim recommendation for use of the Janssen COVID-19 vaccine in all persons aged ≥18 years under the FDA's EUA, which now includes a warning that rare clotting events might occur after vaccination, primarily among women aged 18-49 years. Patient and provider education about the risk for TTS with the Janssen COVID-19 vaccine, especially among women aged <50 years, as well as the availability of alternative COVID-19 vaccines, is required to guide vaccine decision-making and ensure early recognition and clinical management of TTS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259 · cited 10×
“This assessment took into account 1) the rate and characteristics of TTS cases; 2) recent COVID-19 epidemiology; 3) modeling and riskbenefit analysis results to quantify COVID-19 hospitalizations, ICU admissions, and deaths prevented with resumption of use of the Janssen COVID-19 vaccine in the United States; and 4) d…”
ResultInfluential
Cited by
See, I., Su, J. R., Lale, A., Woo, E. J., Guh, A. Y., Shimabukuro, T. T., Streiff, M. B., Rao, A. K., Wheeler, A. P., Beavers, S. F., et al. (2021) · JAMA · doi:10.1001/jama.2021.7517 · Cited by 532
Self-citationAn update on COVID-19 and pregnancy
Jamieson, D. J., & Rasmussen, S. A. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.08.054 · Cited by 466
Incidence of Guillain-Barré syndrome after COVID-19 vaccination in the vaccine safety datalink
Hanson, K. E., Goddard, K., Lewis, N., Fireman, B., Myers, T. R., Bakshi, N., Weintraub, E., Donahue, J. G., Nelson, J. C., Xu, S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8879 · Cited by 160
Frontera, J. A., Tamborska, A. A., Doheim, M. F., Garcia‐Azorin, D., Gezegen, H., Guekht, A., Yusof Khan, A. H. K., Santacatterina, M., Sejvar, J., Thakur, K. T., et al. (2022) · Annals of Neurology · doi:10.1002/ana.26339 · Cited by 108
Metadata
- Authors
- MacNeil, J. R., Su, J. R., Broder, K. R., Guh, A. Y., Gargano, J. W., Wallace, M., Hadler, S. C., Scobie, H. M., Blain, A. E., Moulia, D., Daley, M. F., McNally, V. V., Romero, J. R., Talbot, H. K., Lee, G. M., Bell, B. P., & Oliver, S. E.
- Venue
- MMWR. Morbidity and Mortality Weekly Report
- Published
- 2021-04-30
- Volume
- 70
- Issue
- 17
- Pages
- 651-656
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- OpenAlex
- W3157520343
- Cited by
- 179
- References
- 1
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.